Kwangdong Pharmaceutical, GSK Quadrivalent Influenza Vaccine 'Fluarix Tetra' Sold Domestically

[Asia Economy Reporter Kim Ji-hee] Kwangdong Pharmaceutical announced on the 24th that it has signed a domestic sales and distribution contract for the influenza prevention vaccine ‘Fluarix Tetra’ with the global pharmaceutical company GlaxoSmithKline (GSK).

Under this contract, Kwangdong Pharmaceutical will be responsible for the sales and supply of Fluarix Tetra to all hospitals and clinics in Korea that administer influenza vaccinations. Since 2015, Kwangdong Pharmaceutical has been co-selling eight pediatric vaccine items from GSK.

Fluarix Tetra is the first inactivated quadrivalent influenza vaccine approved by the U.S. FDA. It is produced in Germany and imported as a finished product. It was also the first quadrivalent influenza prevention vaccine approved domestically in 2014, recording sales of 13.6 billion KRW last year alone.

A Kwangdong Pharmaceutical official stated, “In a situation where the importance of influenza prevention is increasing due to COVID-19, we will strive to contribute to public health,” adding, “It is also meaningful as an opportunity to further strengthen the business relationship based on the six years of continuous cooperation between the two companies.”

This content was produced with the assistance of AI translation services.